Abstract Glyceryl phenylbutyrate (GPB) serves as a long-term management medication for Ornithine transcarbamylase deficiency (OTCD), effectively controlling hyperammonemia, but there is a lack of experience in using this medicine in China. This article retrospectively analyzes the case of a child diagnosed with OTCD at Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, including a review of related literature. After diagnosis, the patient was treated with GPB, followed by efficacy follow-up and pharmacological monitoring. The 6-year and 6-month-old male patient exhibited poor speech development, disobedience, temper tantrums, and aggressive behavior. Blood ammonia levels peaked at 327 μmol/L; urine organic acid analysis indicated elevated uracil levels; cranial MRI showed extensive abnormal signals in both cerebral hemispheres. Genetic testing revealed de novo mutation in the OTC gene (c.241T>C, p.S81P). Blood ammonia levels were approximately 43, 80, and 56 μmol/L at 1, 2, and 3 months after starting GPB treatment, respectively. During treatment, blood ammonia was well-controlled without drug-related adverse effects. The patient showed improvement in developmental delays, obedience, temperament, and absence of aggressive behavior.
YANG Fan,WANG Li-Rui,LI Xin et al. Treatment of ornithine transcarbamylase deficiency in a child with glyceryl phenylbutyrate[J]. CJCP, 2024, 26(5): 512-517.
YANG Fan,WANG Li-Rui,LI Xin et al. Treatment of ornithine transcarbamylase deficiency in a child with glyceryl phenylbutyrate[J]. CJCP, 2024, 26(5): 512-517.
Yeo M, Rehsi P, Dorman M, et al. Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre[J]. JIMD Rep, 2023, 64(5): 317-326. PMID: 37701329. PMCID: PMC10494499. DOI: 10.1002/jmd2.12386.
Longo N, Diaz GA, Lichter-Konecki U, et al. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders[J]. Mol Genet Metab, 2021, 132(1): 19-26. PMID: 33388234. PMCID: PMC8655853. DOI: 10.1016/j.ymgme.2020.12.002.
Martín-Hernández E, Quijada-Fraile P, Correcher P, et al. Switching to glycerol phenylbutyrate in 48 patients with urea cycle disorders: clinical experience in Spain[J]. J Clin Med, 2022, 11(17): 5045. PMID: 36078975. PMCID: PMC9457033. DOI: 10.3390/jcm11175045.
Diaz GA, Schulze A, Longo N, et al. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients[J]. Mol Genet Metab, 2019, 127(4): 336-345. PMID: 31326288. DOI: 10.1016/j.ymgme.2019.07.004.
Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes[J]. Mol Genet Metab, 2014, 112(1): 17-24. PMID: 24630270. PMCID: PMC4382922. DOI: 10.1016/j.ymgme.2014.02.007.
Berry SA, Longo N, Diaz GA, et al. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2 months to 2 years[J]. Mol Genet Metab, 2017, 122(3): 46-53. PMID: 28916119. DOI: 10.1016/j.ymgme.2017.09.002.
H?berle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192-1230. PMID: 30982989. DOI: 10.1002/jimd.12100.
